Effect of Maridebart Cafraglutide on the Heart's Electrical Activity

Exclusion Criteria

• •Participants will not be able to take part if they meet any of the following:
• •Medical Conditions
• •1. Any significant medical condition or abnormal test result that, in the opinion of the investigator, could pose a risk or interfere with trial participation.
• •2. History of diabetes (any type, except past gestational diabetes), or Haemoglobin A1c (HbA1c) ≥ 6.5% at screening.
• •3. History of pancreatitis within the past year, or high blood tests suggesting pancreatic problems (lipase/amylase \> 2× normal, or fasting triglycerides \> 500 mg/dL).
• •4. Liver enzymes (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) more than 2× the upper limit of normal.
• •5. Kidney function (estimated glomerular filtration rate \[eGFR\]) \< 70 mL/min/1.73 m\^2.
• •6. Cancer within the last 5 years (except treated nonmelanoma skin cancers or in situ cervical/breast lesions).
• •7. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2.
• •8. Uncontrolled thyroid disease (abnormal thyroid-stimulating hormone \[TSH\] outside 0.4-6.0 mIU/L).
• •9. Contraindications to moxifloxacin, including history of tendon disorders with quinolone use.
• •10. History of gastrointestinal surgery or disease that may affect absorption of oral drugs (other than uncomplicated appendectomy or hernia repair).
• •11. Inability to swallow pills.
• •12. History of significant esophageal, stomach, or bowel disorders (eg, ulcers, bleeding, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis).
• •13. Current or recent suicidal thoughts (per Columbia Suicide Severity Rating Scale \[C-SSRS\]).
• •14. Lifetime history of suicide attempt or behavior.
• •15. Major depressive disorder within the past 2 years.
• •16. History of other serious psychiatric disorders (eg, schizophrenia, bipolar disorder).
• •17. High depression score (patient health questionnaire-9 \[PHQ-9\] ≥ 15).
• •18. History or current signs of heart disease (eg, heart attack, congenital defects, valve disease, angina, bypass or stent).
• •19. History of ischemic optic neuropathy (eye damage from poor blood flow).
• •20. Diagnosis of sleep apnea. Diagnostic Tests
• •21. Positive test for human immunodeficiency virus (HIV).
• •22. Positive test for hepatitis B or C (exceptions apply for prior vaccination or resolved infection).
• •23. Abnormal vital signs: average blood pressure \> 140/90 mmHg or \< 90/50 mmHg, or heart rate \> 110 or \< 40 bpm.
• •24. Abnormal ECG findings at screening or check-in, including:
• •* QTcF \> 450 ms (males) or \> 470 ms (females).
• •* QRS \> 120 ms, PR \> 220 ms, AV block (2nd or 3rd degree).
• •* Findings that make QTc measurement unreliable.
• •* Risk factors for dangerous arrhythmias (eg, heart failure, low potassium, long QT syndrome).
• •* Clinically significant arrhythmias. Medications
• •25. Use of drugs that affect absorption, metabolism, or elimination within 30 days of dosing.
• •26. Use of drugs known to prolong QT/QTc within 30 days of dosing.
• •27. Use of prescription drugs (other than hormone replacement or contraception) within 14 days of dosing.
• •28. Use of long-acting/slow-release medicines still active within 14 days of dosing.
• •29. Use of non-prescription products (vitamins, supplements, herbal products) within 7 days of dosing.
• •30. Use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/antagonists within 3 months of check-in.
• •Other Clinical Trial Experience
• •31. Participation in another investigational drug trial within 30 days or 5 drug half-lives (whichever is longer).
• •32. Previous exposure to maridebart cafraglutide in this or another trial. Lifestyle
• •33. Alcohol use \> 21 units/week (men) or \> 14 units/week (women).
• •34. Alcohol use within 48 hours before check-in.
• •35. Positive drug screen or alcohol test at screening or check-in.
• •36. History of alcohol or drug abuse within 1 year.
• •37. Use of tobacco/nicotine products within 3 months, or positive cotinine test.
• •38. Use of caffeine within 48 hours of screening or check-in.
• •39. Consumption of grapefruit, Seville orange, or related products within 7 days of check-in.
• •40. Consumption of poppy seed-containing foods within 7 days of check-in. Other
• •41. Receipt of blood products within 2 months before check-in.
• •42. Blood donation within 3 months; plasma donation within 2 weeks; platelet donation within 6 weeks.
• •43. Poor veins for blood draws.
• •44. Any other reason, in the opinion of the investigator, the participant should not take part.